These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24149943)

  • 1. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
    Thomas SK; Suvorov A; Noens L; Rukavitsin O; Fay J; Wu KL; Zimmerman TM; van de Velde H; Bandekar R; Puchalski TA; Qi M; Uhlar C; Samoylova OS
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):35-42. PubMed ID: 24149943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
    Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
    Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
    Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.
    Wichert S; Juliusson G; Johansson Å; Sonesson E; Teige I; Wickenberg AT; Frendeus B; Korsgren M; Hansson M
    PLoS One; 2017; 12(2):e0171205. PubMed ID: 28158311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Hudes G; Tagawa ST; Whang YE; Qi M; Qin X; Puchalski TA; Reddy M; Cornfeld M; Eisenberger M
    Invest New Drugs; 2013 Jun; 31(3):669-76. PubMed ID: 22828917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
    Hermouet S; Bigot-Corbel E; Harb J
    Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes in biclonal gammopathies.
    Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
    Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
    Landgren O; Rajkumar SV
    Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.